Drug Profile


Alternative Names: AO 33

Latest Information Update: 08 Sep 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr. Willmar Schwabe Group
  • Class Antiepileptic drugs; Furans; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Partial epilepsies

Most Recent Events

  • 06 Sep 2005 Discontinued - Phase-III for Partial seizures in European Union (PO)
  • 06 Sep 2005 Discontinued - Phase-III for Partial seizures in USA (PO)
  • 29 Jan 2003 Losigamone is available for licensing (www.schwabepharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top